Benefits and challenges with diagnosing chronic and late acute GVHD in children using the NIH consensus criteria.


Journal

Blood
ISSN: 1528-0020
Titre abrégé: Blood
Pays: United States
ID NLM: 7603509

Informations de publication

Date de publication:
18 07 2019
Historique:
received: 18 02 2019
accepted: 25 04 2019
pubmed: 3 5 2019
medline: 15 1 2020
entrez: 3 5 2019
Statut: ppublish

Résumé

Chronic graft-versus-host disease (cGVHD) and late acute graft-versus-host disease (L-aGVHD) are understudied complications of allogeneic hematopoietic stem cell transplantation in children. The National Institutes of Health Consensus Criteria (NIH-CC) were designed to improve the diagnostic accuracy of cGVHD and to better classify graft-versus-host disease (GVHD) syndromes but have not been validated in patients <18 years of age. The objectives of this prospective multi-institution study were to determine: (1) whether the NIH-CC could be used to diagnose pediatric cGVHD and whether the criteria operationalize well in a multi-institution study; (2) the frequency of cGVHD and L-aGVHD in children using the NIH-CC; and (3) the clinical features and risk factors for cGVHD and L-aGVHD using the NIH-CC. Twenty-seven transplant centers enrolled 302 patients <18 years of age before conditioning and prospectively followed them for 1 year posttransplant for development of cGVHD. Centers justified their cGVHD diagnosis according to the NIH-CC using central review and a study adjudication committee. A total of 28.2% of reported cGVHD cases was reclassified, usually as L-aGVHD, following study committee review. Similar incidence of cGVHD and L-aGVHD was found (21% and 24.7%, respectively). The most common organs involved with diagnostic or distinctive manifestations of cGVHD in children include the mouth, skin, eyes, and lungs. Importantly, the 2014 NIH-CC for bronchiolitis obliterans syndrome perform poorly in children. Past acute GVHD and peripheral blood grafts are major risk factors for cGVHD and L-aGVHD, with recipients ≥12 years of age being at risk for cGVHD. Applying the NIH-CC in pediatrics is feasible and reliable; however, further refinement of the criteria specifically for children is needed.

Identifiants

pubmed: 31043425
pii: S0006-4971(20)42402-4
doi: 10.1182/blood.2019000216
pmc: PMC6911839
doi:

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

304-316

Subventions

Organisme : NCI NIH HHS
ID : P30 CA022453
Pays : United States
Organisme : CIHR
ID : 255075
Pays : Canada

Commentaires et corrections

Type : CommentIn

Informations de copyright

© 2019 by The American Society of Hematology.

Références

Biol Blood Marrow Transplant. 2015 Aug;21(8):1524-8
pubmed: 25963919
Blood. 2002 Aug 15;100(4):1192-200
pubmed: 12149197
Biol Blood Marrow Transplant. 2011 Feb;17(2):167-75
pubmed: 20691801
N Engl J Med. 2017 Dec 28;377(26):2565-2579
pubmed: 29281578
Biol Blood Marrow Transplant. 2015 Feb;21(2):266-74
pubmed: 25445023
Blood. 2014 Jul 31;124(5):822-6
pubmed: 24869942
Blood. 2018 Dec 13;132(24):2594-2607
pubmed: 30348653
N Engl J Med. 2000 Jun 22;342(25):1846-54
pubmed: 10861319
Am J Transplant. 2016 Aug;16(8):2342-51
pubmed: 26887344
Blood. 2011 Aug 4;118(5):1413-20
pubmed: 21652685
Biol Blood Marrow Transplant. 2014 Apr;20(4):556-63
pubmed: 24447907
Blood. 2011 Apr 28;117(17):4651-7
pubmed: 21355084
Biol Blood Marrow Transplant. 2002;8(1):32-9
pubmed: 11846354
Blood. 2007 Nov 15;110(10):3784-92
pubmed: 17671231
Biol Blood Marrow Transplant. 2016 Mar;22(3):449-55
pubmed: 26541363
Blood. 2011 Oct 13;118(15):4242-9
pubmed: 21791424
Bone Marrow Transplant. 2018 Nov;53(11):1401-1415
pubmed: 29872128
Biol Blood Marrow Transplant. 2005 Dec;11(12):945-56
pubmed: 16338616
Bone Marrow Transplant. 2001 Dec;28(11):1047-51
pubmed: 11781615
Biol Blood Marrow Transplant. 2015 Nov;21(11):1973-80
pubmed: 26234723
Am J Med. 1980 Aug;69(2):204-17
pubmed: 6996481
Biol Blood Marrow Transplant. 2015 Apr;21(4):604-11
pubmed: 25240817
Bone Marrow Transplant. 2014 Jan;49(1):49-54
pubmed: 23955633
Bone Marrow Transplant. 1995 Jun;15(6):825-8
pubmed: 7581076
Biol Blood Marrow Transplant. 2017 Feb;23(2):325-332
pubmed: 27888014
Haematologica. 2018 Nov;103(11):1915-1924
pubmed: 29954931
Blood. 2017 Jan 5;129(1):30-37
pubmed: 27821503
Yonsei Med J. 2011 Sep;52(5):779-86
pubmed: 21786443
Blood. 2006 Oct 15;108(8):2867-73
pubmed: 16788100
Curr Hematol Malig Rep. 2015 Sep;10(3):183-91
pubmed: 26303672
Biol Blood Marrow Transplant. 2015 May;21(5):780-92
pubmed: 25644957
J Clin Oncol. 2004 Dec 15;22(24):4872-80
pubmed: 15520055
Bone Marrow Transplant. 2019 Jul;54(7):994-1003
pubmed: 30337699
Blood. 2011 Oct 20;118(16):4472-9
pubmed: 21878671
Haematologica. 2011 Nov;96(11):1678-84
pubmed: 21791465
Can J Kidney Health Dis. 2017 Feb 16;4:2054358117690338
pubmed: 28270931
Biol Blood Marrow Transplant. 2017 Feb;23(2):211-234
pubmed: 27713092
Br J Haematol. 2010 Aug;150(3):278-92
pubmed: 20553274
Biol Blood Marrow Transplant. 2010 Jan;16(1):108-14
pubmed: 19772943
Cancer. 2015 Dec 1;121(23):4250-7
pubmed: 26288023
Blood. 2013 Mar 7;121(10):1886-95
pubmed: 23303823
Biol Blood Marrow Transplant. 2018 Nov;24(11):2285-2292
pubmed: 30031937
Bone Marrow Transplant. 2014 Apr;49(4):532-8
pubmed: 24464142
Biol Blood Marrow Transplant. 2009 Dec;15(12):1628-33
pubmed: 19896087
Biol Blood Marrow Transplant. 2013 Apr;19(4):632-9
pubmed: 23340040
Biol Blood Marrow Transplant. 2015 Mar;21(3):389-401.e1
pubmed: 25529383
Bone Marrow Transplant. 2019 Jan;54(1):76-84
pubmed: 30089900
Biol Blood Marrow Transplant. 2016 May;22(5):895-901
pubmed: 26860634
Biol Blood Marrow Transplant. 2014 Oct;20(10):1592-8
pubmed: 24954547

Auteurs

Geoffrey D E Cuvelier (GDE)

CancerCare Manitoba, University of Manitoba, Winnipeg, MB, Canada.

Eneida R Nemecek (ER)

Pediatric Blood and Marrow Transplant, Doernbechter Children's Hospital, Oregon Health and Science University, Portland, OR.

Justin T Wahlstrom (JT)

Benioff Children's Hospital, University of California San Francisco, San Francisco, CA.

Carrie L Kitko (CL)

Vanderbilt University Medical Center, Nashville, TN.

Victor A Lewis (VA)

Alberta Children's Hospital, University of Calgary, Calgary, AB, Canada.

Tal Schechter (T)

Hospital for Sick Children, University of Toronto, Toronto, ON, Canada.

David A Jacobsohn (DA)

Children's National Health System, Washington, DC.

Andrew C Harris (AC)

Primary Children's Hospital, University of Utah, Salt Lake City, UT.

Michael A Pulsipher (MA)

Children's Hospital Los Angeles, Los Angeles, CA.

Henrique Bittencourt (H)

Ste. Justine University Hospital Center, Montreal, QC, Canada.

Sung Won Choi (SW)

C.S. Mott Children's Hospital, Michigan Medicine, Ann Arbor, MI.

Emi H Caywood (EH)

Nemours Alfred I. duPont Hospital for Children, Wilmington, DE.

Kimberly A Kasow (KA)

Division of Pediatric Hematology-Oncology, University of North Carolina at Chapel Hill, Chapel Hill, NC.

Monica Bhatia (M)

Morgan Stanley Children's Hospital, Columbia University, New York, NY.

Benjamin R Oshrine (BR)

Johns Hopkins All Children's Hospital, St. Petersburg, FL.

Allyson Flower (A)

New York Medical College, Valhalla, NY.

Sonali Chaudhury (S)

Ann & Robert H. Lurie Children's Hospital, Northwestern University, Chicago, IL.

Donald Coulter (D)

University of Nebraska Medical Center, Omaha, NE.

Joseph H Chewning (JH)

Division of Pediatric Hematology-Oncology, Children's of Alabama, University of Alabama at Birmingham, Birmingham, AL.

Michael Joyce (M)

Nemours Children's Specialty Care, Jacksonville, FL.

Süreyya Savaşan (S)

Children's Hospital of Michigan, Detroit, MI.

Anna B Pawlowska (AB)

City of Hope, Duarte, CA.

Gail C Megason (GC)

University of Mississippi Medical Center, Jackson, MS.

David Mitchell (D)

Montreal Children's Hospital, Montreal, QC, Canada.

Alexandra C Cheerva (AC)

Norton Children's Hospital, University of Louisville, Louisville, KY.

Anita Lawitschka (A)

St. Anna Children's Hospital, Medical University Vienna, Vienna, Austria.

Lori J West (LJ)

Alberta Transplant Institute, University of Alberta, Edmonton, AB, Canada.

Bo Pan (B)

EPICORE Centre, University of Alberta, Edmonton, AB, Canada; and.

Yazid N Al Hamarneh (YN)

EPICORE Centre, University of Alberta, Edmonton, AB, Canada; and.

Anat Halevy (A)

British Columbia Children's Hospital, University of British Columbia, Vancouver, BC, Canada.

Kirk R Schultz (KR)

British Columbia Children's Hospital, University of British Columbia, Vancouver, BC, Canada.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH